Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medeon BiodesignROCO:6499 -1.69%68 Altman Z-Score is 15.33 as of Jul. 13, 2026, which is 2% above its 10-year median of 14.99. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.08 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 809 Medical Devices & Instruments companies, Medeon Biodesign ranks better than 89.99% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 15.33 is strong.
Medeon Biodesign has a Altman Z-Score of 15.33, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Medeon Biodesign's Altman Z-Score or its related term are showing as below:
ROCO:6499'
s Altman Z-Score Range Over the Past 10 Years
Min: 3.65 Med: 14.99 Max: 37.84
Current: 15.33
During the past 13 years, Medeon Biodesign's highest Altman Z-Score was 37.84. The lowest was 3.65. And the median was 14.99.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Medeon Biodesign Altman Z-Score Related Terms
Medeon Biodesign Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Medeon Biodesign's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6499 vs ISRG, BDX, MDLN: Altman Z-Score Comparison
For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeon Biodesign Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Medeon Biodesign's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Medeon Biodesign's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.6524
+
1.4
*
-0.9641
+
3.3
*
-0.4023
+
0.6
*
28.3223
+
1.0
*
0.2357
=
15.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Medeon Biodesign (ROCO:6499) has a Altman Z-Score of 15.33 as of Jul. 13, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Medeon Biodesign and its competitors. This is near median its historical median of 14.99. Over the past decade, Medeon Biodesign's Altman Z-Score has ranged from 3.65 to 37.84. According to the industry distribution chart, Medeon Biodesign ranks #81 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 10%.
Is Medeon Biodesign's Altman Z-Score too high?
Medeon Biodesign's current Altman Z-Score of 15.33 is near median its 10-year median of 14.99. Over the past 10 years, this metric has ranged from a low of 3.65 to a high of 37.84. The Medical Devices & Instruments industry median Altman Z-Score is 3.02. Medeon Biodesign's value of 15.33 is 407.6% above this industry median. Based on the distribution chart, Medeon Biodesign ranks #81 out of 809 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Altman Z-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Medeon Biodesign ranks #81 out of 809 companies for Altman Z-Score. This places Medeon Biodesign in the top 10% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.02. Medeon Biodesign's value of 15.33 is 407.6% above this benchmark. Historically, Medeon Biodesign's own Altman Z-Score has ranged from 3.65 to 37.84 over the past decade. While the company's 10-year median is 14.99 vs. the industry median of 3.02, Medeon Biodesign has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.02, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeon Biodesign's current Altman Z-Score of 15.33 is 407.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Medeon Biodesign and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current Altman Z-Score is 15.33, which is near median its own 10-year median of 14.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.08, compared to a current price of NT$69.80 — trading 34.8% below its estimated fair value. The current Altman Z-Score is 15.33, which is near median its 10-year median of 14.99 and 407.6% above the Medical Devices & Instruments industry median of 3.02. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Altman Z-Score is 15.33 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?
Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued.
The current stock price of NT$69.80 is trading 34.8% below its estimated GF Value™ of NT$107.08.
GuruFocus considers Medeon Biodesign to be Significantly Undervalued.
Key valuation signals for ROCO:6499:
Altman Z-Score: 15.33 (near median its 10-year median of 14.99)
GF Value™: NT$107.08 vs. price of NT$69.80 (34.8% below fair value)
Industry Position: 407.6% above the Medical Devices & Instruments median (#81 of 809)
No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
68GF Score
Get the complete analysis for ROCO:6499
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6499 has been successfully added to your 
